 | • レポートコード：MRC2305B189 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、234ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に2,193.78百万ドルであった世界の化学療法誘発性貧血市場規模が、2022年には2,349.11百万ドルに達し、2027年までに年平均7.25％成長して3,340.05百万ドルになると予測しています。当調査資料では、化学療法誘発性貧血の世界市場について調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、貧血範囲別分析（致死的貧血、軽度貧血、中程度貧血、重度貧血）、治療種類別分析（赤血球生成刺激剤（ESA）、鉄分補給、赤血球輸血）、薬剤種類別分析（アンドロキシ経口剤、アラネスプ注射剤、エポエチンアルファ注射剤、エポゲン注射剤、プロクリット注射剤）、エンドユーザー別分析（外来手術センター、がんリハビリセンター、がん研究センター、病院、総合クリニック）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの項目をまとめました。なお、当書に掲載されている企業情報には、Amgen Inc.、AOP Orphan Pharmaceuticals AG、Astellas Pharma Inc.、Blausen Medical、Dr. Reddy’s Laboratories Ltd.、Elsevier Inc.、F. Hoffmann-La Roche Ltd、FibroGen, Inc.、GlaxoSmithKline PLC、Healio、Johnson & Johnson、Karger AG、Novartis AGなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の化学療法誘発性貧血市場規模：貧血範囲別 - 致死的貧血の市場規模 - 軽度貧血の市場規模 - 中程度貧血の市場規模 - 重度貧血の市場規模 ・世界の化学療法誘発性貧血市場規模：治療種類別 - 赤血球生成刺激剤（ESA）の市場規模 - 鉄分補給の市場規模 - 赤血球輸血の市場規模 ・世界の化学療法誘発性貧血市場規模：薬剤種類別 - アンドロキシ経口剤の市場規模 - アラネスプ注射剤の市場規模 - エポエチンアルファ注射剤の市場規模 - エポゲン注射剤の市場規模 - プロクリット注射剤の市場規模 ・世界の化学療法誘発性貧血市場規模：エンドユーザー別 - 外来手術センターにおける市場規模 - がんリハビリセンターにおける市場規模 - がん研究センターにおける市場規模 - 病院における市場規模 - 総合クリニックにおける市場規模 ・世界の化学療法誘発性貧血市場規模：地域別 - 南北アメリカの化学療法誘発性貧血市場規模 アメリカの化学療法誘発性貧血市場規模 カナダの化学療法誘発性貧血市場規模 ブラジルの化学療法誘発性貧血市場規模 ... - アジア太平洋の化学療法誘発性貧血市場規模 日本の化学療法誘発性貧血市場規模 中国の化学療法誘発性貧血市場規模 インドの化学療法誘発性貧血市場規模 韓国の化学療法誘発性貧血市場規模 台湾の化学療法誘発性貧血市場規模 ... - ヨーロッパ/中東/アフリカの化学療法誘発性貧血市場規模 イギリスの化学療法誘発性貧血市場規模 ドイツの化学療法誘発性貧血市場規模 フランスの化学療法誘発性貧血市場規模 ロシアの化学療法誘発性貧血市場規模 ... - その他地域の化学療法誘発性貧血市場規模 ・競争状況 ・企業情報 |
The Global Chemotherapy Induced Anemia Market size was estimated at USD 2,193.78 million in 2021 and expected to reach USD 2,349.11 million in 2022, and is projected to grow at a CAGR 7.25% to reach USD 3,340.05 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Chemotherapy Induced Anemia to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Range Of Anemia, the market was studied across Life-Threatening Anemia, Mild Anemia, Moderate Anemia, and Severe Anemia.
Based on Treatment type, the market was studied across Erythropoiesis-stimulating agents (ESAs), Iron Supplementation, and RBC Transfusions.
Based on Drug Type, the market was studied across Androxy Oral, Aranesp Injection, Epoetin Alfa Injection, Epogen Injection, and Procrit Injection.
Based on End-user, the market was studied across Ambulatory Surgical Centers, Cancer Rehabilitation Centers, Cancer Research Centers, Hospitals, and Multispecialty Clinics.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Chemotherapy Induced Anemia market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Chemotherapy Induced Anemia Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Chemotherapy Induced Anemia Market, including Amgen Inc., AOP Orphan Pharmaceuticals AG, Astellas Pharma Inc., Blausen Medical, Dr. Reddy’s Laboratories Ltd., Elsevier Inc., F. Hoffmann-La Roche Ltd, FibroGen, Inc., GlaxoSmithKline PLC, Healio, Johnson & Johnson, Karger AG, Novartis AG, Pfizer Inc., Pharmacosmos A/S, PhytoHealth Corporation, SBI Pharmaceuticals Co., Ltd, Springer Nature Limited, Therapure Biopharma Inc., Tracxn Technologies Private Limited, and Vifor Pharma AG.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Chemotherapy Induced Anemia Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Chemotherapy Induced Anemia Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Chemotherapy Induced Anemia Market?
4. What is the competitive strategic window for opportunities in the Global Chemotherapy Induced Anemia Market?
5. What are the technology trends and regulatory frameworks in the Global Chemotherapy Induced Anemia Market?
6. What is the market share of the leading vendors in the Global Chemotherapy Induced Anemia Market?
7. What modes and strategic moves are considered suitable for entering the Global Chemotherapy Induced Anemia Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer and anemia among geriatric patients
5.1.1.2. Increasing availability of number of chemotherapy agents
5.1.2. Restraints
5.1.2.1. Risk and severity of anemia during chemotherapy
5.1.3. Opportunities
5.1.3.1. Innovations in the field of chemotherapy induced anemia
5.1.3.2. Rising government initiatives, and technologically advanced healthcare infrastructure
5.1.4. Challenges
5.1.4.1. Lower efficacy of the chemotherapy induced thrombocytopenia treating drugs
5.2. Cumulative Impact of COVID-19
6. Chemotherapy Induced Anemia Market, by Range Of Anemia
6.1. Introduction
6.2. Life-Threatening Anemia
6.3. Mild Anemia
6.4. Moderate Anemia
6.5. Severe Anemia
7. Chemotherapy Induced Anemia Market, by Treatment type
7.1. Introduction
7.2. Erythropoiesis-stimulating agents (ESAs)
7.3. Iron Supplementation
7.4. RBC Transfusions
8. Chemotherapy Induced Anemia Market, by Drug Type
8.1. Introduction
8.2. Androxy Oral
8.3. Aranesp Injection
8.4. Epoetin Alfa Injection
8.5. Epogen Injection
8.6. Procrit Injection
9. Chemotherapy Induced Anemia Market, by End-user
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Cancer Rehabilitation Centers
9.4. Cancer Research Centers
9.5. Hospitals
9.6. Multispecialty Clinics
10. Americas Chemotherapy Induced Anemia Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Chemotherapy Induced Anemia Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Chemotherapy Induced Anemia Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Amgen Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. AOP Orphan Pharmaceuticals AG
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Astellas Pharma Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Blausen Medical
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Dr. Reddy’s Laboratories Ltd.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Elsevier Inc.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. F. Hoffmann-La Roche Ltd
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. FibroGen, Inc.
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. GlaxoSmithKline PLC
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Healio
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Johnson & Johnson
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Karger AG
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Novartis AG
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Pfizer Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Pharmacosmos A/S
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. PhytoHealth Corporation
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. SBI Pharmaceuticals Co., Ltd
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Springer Nature Limited
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Therapure Biopharma Inc.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Tracxn Technologies Private Limited
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Vifor Pharma AG
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing